FDC Ltd. Revenue Breakdown – NSE:FDC
NiveshIQ
NSE: FDC
FDC Ltd.
₹407.65▼ ₹6.65 (-1.61%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on FDC. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About FDC Ltd.
FDC Limited is a leading Indian pharmaceutical company with a diversified portfolio of products across various therapeutic segments. The company generates revenue primarily from the sale of its pharmaceutical formulations, which account for approximately 75% of its total revenue. FDC offers a wide range of products, including tablets, capsules, oral liquids, and paediatric-friendly solutions, under its various brands such as Zifi, Zefu, and Zocon. The company also exports its products to several countries, including the United States and internationally. However, FDC has faced recent challenges, including a seizure of its Enerzal stock by the Maharashtra FDA over misbranding allegations. Despite this, the company continues to maintain a strong presence in the Indian pharmaceutical market.
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,942 Cr +8.90% | ₹2,108 Cr +8.50% | ₹2,171 Cr +3.00% |
| EBITDA Margin | 17.40% | 15.09% | 21.17% |
| Net Profit | ₹305.00 Cr +57.20% | ₹267.00 Cr -12.50% | ₹281.42 Cr +5.40% |
| EPS | ₹18.62 | ₹16.39 | ₹17.29 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Maharashtra FDA Seizes FDC Enerzal Stock Over Misbranding Allegations
🔒
Sign in to see AI summaries
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹668 Cr, PAT ₹132 Cr, EPS ₹8.14, EBITDA margin 28.6%. Growth context: revenue QoQ +14.2%, PAT QoQ +28.1%.
Product launches, approvals, and therapy-mix improvements are poised to drive the next leg of growth, with management hi...
FY26 (last completed FY): revenue ₹2, 171 Cr, PAT ₹281 Cr, EBITDA margin 21.2%, EPS ₹17.29. Year-on-year: revenue YoY +3...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for FDC
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track FDC alongside your other holdings
Unlock full FDC research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for FDC Ltd.?
NiveshIQ detects active intelligence signals for FDC Ltd. (FDC) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for FDC Ltd.?
FDC Ltd. is listed on NSE/BSE with a market capitalisation of ₹663,695.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.